CASI Pharmaceuticals (CASIF) Retained Earnings (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Retained Earnings came in at -$1.8 million in Q4 2025, down 0.62% YoY from -$1.8 million in Q4 2024, and up 99.76% on a QoQ basis from -$735.1 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Retained Earnings (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Retained Earnings data on file, last reported at -$1.8 million in Q4 2025.
- Quarterly Retained Earnings fell 0.62% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.8 million (down 0.62% YoY) and the FY2025 annual result came in at -$1.8 million, down 0.62% from the prior year.
- Retained Earnings rose to -$1.8 million in Q4 2025, from -$735.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1.8 million in Q4 2024 to a low of -$710.8 billion in Q1 2025.
- A 5-year average of -$245.8 billion and a median of -$724.2 million in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 100.0% — and 2025, when it slumped 105938.68%.
- Tracing CASIF's Retained Earnings over 5 years: stood at -$605.6 million in 2021, then retreated by 5.2% to -$637.2 million in 2022, then plunged by 103612.88% to -$660.8 billion in 2023, then surged by 100.0% to -$1.8 million in 2024, then retreated by 0.62% to -$1.8 million in 2025.
- The last three Retained Earnings figures came in at -$1.8 million (Q4 2025), -$735.1 million (Q3 2025), and -$724.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | -768.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | -735.09 Mn |
| Jun 30, 2025 | -724.20 Mn |
| Mar 31, 2025 | -710.83 Bn |
| Dec 31, 2024 | -1.77 Mn |
| Jun 30, 2024 | -677.31 Bn |
| Mar 31, 2024 | -670.35 Mn |
| Dec 31, 2023 | -660.82 Bn |
| Jun 30, 2023 | -651.80 Bn |
| Dec 31, 2022 | -637.16 Mn |
| Dec 31, 2021 | -605.64 Mn |